Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Free Cash Flow (2020 - 2025)

Apellis Pharmaceuticals has reported Free Cash Flow over the past 6 years, most recently at -$14.3 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$14.3 million for Q4 2025, down 173.86% from a year ago — trailing twelve months through Dec 2025 was $45.0 million (up 151.0% YoY), and the annual figure for FY2025 was $45.0 million, up 151.0%.
  • Free Cash Flow for Q4 2025 was -$14.3 million at Apellis Pharmaceuticals, down from $108.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for APLS hit a ceiling of $108.3 million in Q3 2025 and a floor of -$177.9 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was -$112.1 million (2021), compared with a mean of -$85.9 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 179.65% in 2021 and later surged 217.69% in 2025.
  • Apellis Pharmaceuticals' Free Cash Flow stood at -$112.5 million in 2021, then fell by 25.84% to -$141.6 million in 2022, then soared by 30.81% to -$98.0 million in 2023, then surged by 119.74% to $19.3 million in 2024, then crashed by 173.86% to -$14.3 million in 2025.
  • The last three reported values for Free Cash Flow were -$14.3 million (Q4 2025), $108.3 million (Q3 2025), and $4.4 million (Q2 2025) per Business Quant data.